TORRANCE, Calif., April 15, 2025 /PRNewswire/ — Compex Legal Services, a leading national provider of medical records retrieval and litigation support services, proudly announces the launch of Compex Canvass™, a cutting-edge medical canvassing solution designed to deliver faster, deeper insight into claimants’ medical histories.
Compex Canvass™ represents a significant step forward in investigative solutions for the insurance, legal, and risk management industries. By leveraging a robust network and proprietary research processes, the new service enables clients to quickly identify undisclosed or pre-existing treatments across a wide range of healthcare providers, including hospitals, urgent care centers, pharmacies, and physicians, nationwide.
“We developed Compex Canvass™ in response to the growing demand for more efficient and accurate medical canvassing,” said Joshua Rosenberg, Chief Growth Officer at Compex Legal Services. “Our goal is to give clients a smarter way to validate medical claims, reduce fraud, and make informed decisions with confidence.”
Compex Canvass™ empowers users to act swiftly while minimizing risk. It integrates seamlessly into the broader suite of Compex solutions, providing a cohesive experience across claims and legal support processes.
Key Benefits of Compex Canvass™ Include:
With this launch, Compex continues to demonstrate its commitment to innovation, client service, and industry leadership.
For more information about Compex Canvass™ or to request a demo, visit www.compexlegal.com/medical-canvassing
Media Contact:
Kevin Plankey
Director of Marketing
Compex Legal Services
kevin.plankey@compexlegal.com
SOURCE Compex Legal Services
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…